Regeneron Pharmaceuticals, Inc. (REGN) Position Increased by First Trust Advisors LP
First Trust Advisors LP raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,424 shares of the biopharmaceutical company’s stock after buying an additional 16,638 shares during the period. First Trust Advisors LP’s holdings in Regeneron Pharmaceuticals were worth $54,234,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in the stock. Korea Investment CORP increased its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the last quarter. FNY Managed Accounts LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $140,000. Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. IFP Advisors Inc boosted its position in shares of Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Wendell David Associates Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $204,000. 66.70% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at 466.59 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The company’s 50-day moving average price is $495.54 and its 200-day moving average price is $426.50. The firm has a market cap of $49.47 billion, a PE ratio of 46.81 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.84 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/13/regeneron-pharmaceuticals-inc-regn-position-increased-by-first-trust-advisors-lp.html.
Several equities analysts have recently issued reports on the company. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target on the stock. in a research report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 price target (up from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Leerink Swann reiterated an “outperform” rating and set a $580.00 price target (up from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target on the stock in a research report on Wednesday. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $489.35.
In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares in the company, valued at approximately $23,405,572.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Robert E. Landry sold 526 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the transaction, the senior vice president now owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,922 shares of company stock valued at $27,383,105. Corporate insiders own 10.40% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.